• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

47.27 +1.65 (+3.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,820,759
Open 45.63
Bid (Size) 46.50 (3)
Ask (Size) 47.25 (1)
Prev. Close 45.62
Today's Range 45.55 - 48.06
52wk Range 21.72 - 48.68
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
July 30, 2025
 
Via Benzinga
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1
July 23, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Performance

YTD
+67.6%
+67.6%
1 Month
+10.5%
+10.5%
3 Month
+23.1%
+23.1%
6 Month
+31.4%
+31.4%
1 Year
+82.2%
+82.2%

More News

Read More
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
July 22, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For April 29, 2025
April 29, 2025
Via Benzinga
A Look Ahead: BridgeBio Pharma's Earnings Forecast
April 28, 2025
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 15, 2025
Via Benzinga
Is Pfizer Stock a Yield Trap?
July 03, 2025
Via The Motley Fool
Topics Intellectual Property
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
June 30, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
June 26, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
June 05, 2025
Via The Motley Fool
Topics Intellectual Property Retirement
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
June 02, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
The Smart Money Is Buying These 10 Stocks
May 20, 2025
Via Benzinga
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
May 20, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
May 19, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 14, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
May 13, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
May 12, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
May 07, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
May 02, 2025
Via Benzinga
Topics World Trade
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
April 29, 2025
Via Investor's Business Daily
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
April 29, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
April 28, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
April 22, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
March 31, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?
Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.
What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?
BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?
The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market
What is the current price of BridgeBio Pharma, Inc. - Common Stock?
The current price of BridgeBio Pharma, Inc. - Common Stock is 47.27
When was BridgeBio Pharma, Inc. - Common Stock last traded?
The last trade of BridgeBio Pharma, Inc. - Common Stock was at 07/31/25 04:00 PM ET
What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?
The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 7.59B
How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?
BridgeBio Pharma, Inc. - Common Stock has 8B shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap